<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01886469</url>
  </required_header>
  <id_info>
    <org_study_id>HLD100-102</org_study_id>
    <secondary_id>HLD100-102 (Control # 163513)</secondary_id>
    <nct_id>NCT01886469</nct_id>
  </id_info>
  <brief_title>A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironshore Pharmaceuticals and Development, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironshore Pharmaceuticals and Development, Inc</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the rate and extent of absorption of one or
      more modified release formulations of amphetamine (HLD100) in both adolescents and children
      with ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extent of absorption of d-amphetamine (AUC0-tz, AUC0-∞, Cmax, Tmax, absorption lag time, λz, and t1/2elim)</measure>
    <time_frame>48hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AEs, ECG, laboratory parameters, physical examinations)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Attention-Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Adolescents (12-17yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Children (6-11 yrs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLD100-B</intervention_name>
    <description>d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)</description>
    <arm_group_label>Adolescents (12-17yrs)</arm_group_label>
    <arm_group_label>Children (6-11 yrs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLD100-C</intervention_name>
    <description>d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.</description>
    <arm_group_label>Adolescents (12-17yrs)</arm_group_label>
    <arm_group_label>Children (6-11 yrs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLD100-E</intervention_name>
    <description>d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.</description>
    <arm_group_label>Adolescents (12-17yrs)</arm_group_label>
    <arm_group_label>Children (6-11 yrs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria

          -  Male and female adolescents (12-17 years; Stage 1) and children (6-11 years; Stage 2).

          -  Diagnosis of ADHD and confirmed on Kiddie-Schedule for Affective Disorders and
             Schizophrenia (K-SADS).

          -  ADHD symptoms controlled on a stable dose of Vyvanse, Adderall XR and or Dexedrine.

          -  Provision of informed consent (from parent[s] or legal representative[s]) and assent
             (from subject) for patients.

        Main Exclusion Criteria

          -  Comorbid psychiatric diagnosis (e.g., psychosis, bipolar disorder).

          -  History of seizures or current diagnosis or family history of Tourette's disorder.

          -  Use of prescription drugs (except Vyvanse, Dexedrine or Adderall XR) the 14 days and
             over-the-counter drugs (except birth control) the 30 days before the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saskatoon Centre for Patient-Oriented Research, Royal University Hospital, Room 5681, C Wing</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>October 2, 2014</last_update_submitted>
  <last_update_submitted_qc>October 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

